Sutura is focussed on developing a world-leading pipeline of precision gene medicines using our proprietary technology, in order to transform patients’ lives around the world.
Developing therapeutics that target RNA defines a new class of medicines with the flexibility to address a wide range of therapeutics areas. Our proprietary delivery technologies enable us to innovate new medicines based on antisense oligonucleotides, positively impacting the lives of patients struggling with debilitating and life-threatening conditions.
The Beauty of Antisense Oligonucleotide Technology
Antisense gene medicines are engineered to bind to RNA, the ‘beauty’ of this technology lies in its precision, with minimal off-target effects. The binding of the antisense gene medicine can either turn off a disease causing protein or turn up a protein, if not enough protein is causing disease.
A New Class of Precision Gene Medicines
Antisense oligonucleotide gene medicines historically have had problems with getting into tissues and cells when administered systemically; Sutura Therapeutics’ delivery technology overcomes this important hurdle. A drug is only a drug if it gets to the right cell in the right quantities without causing side effects.
Sutura Therapeutics has created a new class of precision gene medicines. Our antisense medicines are attached to a ‘cellular magnet’, a short peptide that enhances the ability of the antisense medicine to enter the right cells.
The precision gene medicine, consisting of the ‘cellular magnet’ peptide physically linked to the antisense oligonucleotide, is entirely synthetic, and very stable.